In contrast to P-PSMA-101-00, other immune-oncology therapies modify antibodies' structure to help patients' T cells detect and kill prostate cancer. These modified antibodies bind to prostate cancer, which expresses PSMA on their surface, with the patient's immune cells (i.e., T cells), forming clusters. The clustering of immune cells allows for more effective killing of the cancer cells.
Amgen is presently sponsoring the AMG 160 clinical trial for men with mCRPC. This trial studies how well AMG 160 kills mCRPC alone or with pembrolizumab (Keytruda), another immuno-oncology agent.
To find an actively enrolling clinical trial, which could benefit you, please review the below clinical trials or go to our "Find Your Trial" site, enabling you to check for a trial associated with your diagnosis.